Compare GCT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | ORKA |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2022 | N/A |
| Metric | GCT | ORKA |
|---|---|---|
| Price | $40.10 | $31.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $24.00 | ★ $48.20 |
| AVG Volume (30 Days) | 507.9K | ★ 643.8K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.32 | N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | ★ $1,222,932,000.00 | N/A |
| Revenue This Year | $9.56 | N/A |
| Revenue Next Year | $7.08 | N/A |
| P/E Ratio | $12.26 | ★ N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $11.17 | $5.49 |
| 52 Week High | $43.85 | $32.64 |
| Indicator | GCT | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 61.93 | 53.61 |
| Support Level | $38.89 | $27.84 |
| Resistance Level | $41.50 | $32.64 |
| Average True Range (ATR) | 1.96 | 1.92 |
| MACD | -0.27 | 0.00 |
| Stochastic Oscillator | 40.25 | 56.46 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.